H.R. 3, Prescription drug pricing issues H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 5260 Reduced Costs and Continued Cures Act H.R.5376, Build Back Better Act S2891 Restoring America Invents Act, patent thickets/product hopping HR 4521 Unites States Innovation and Competition Act of 2021 Issues related to FTC Biosimilars reimbursement issues, no specific bill Supply Chain Issues, no specific bill Issues related to clinical trial diversity, HR 6584 DEPICT Act, HR5030 DIVERSE Trials Act Issues related to biodefense issues, S3799 PREVENT Pandemics Act Issues related to cardiovascular disease awareness, no specific bill H.R. 5801 HELP Copays Act Issues related to patient affordability issues, including copay cards, copay accumulators, National Benefit Payment Parameters FDA Issues; User Fee Reauthorization (no specific bill), H.R. 6963, the Accelerated Approval Integrity Act of 2022 H.R. 7047, a bill to amend Title III of the Public Health Service Act with respect to the determination by the Secretary regarding certain biosimilar application elements, and for other purposes H.R. 6000, the Cures 2.0 Act H.R. 7008, the Pre-Approval Information Exchange Act S. 99 The Medicare Drug Price Negotiation Act, issues related to international reference pricing and Part D redesign H.R. 3 Lower Drug Costs Now Act, issues related to international reference pricing and Part D redesign H.R. 5376 Build Back Better Act, issues related to international reference pricing and Part D redesign S. 1943 and H.R. 3517, Issues related to DXA, osteoporosis HR 2471 Consolidated Appropriations Act 2022, Issues related to the 340B program HR 2471, Consolidated appropriations Act of 2022, ESRD bundle, calcimimetic access H.R. 19 Lower Costs, More Cures Act of 2021, issues related to international reference pricing and Part D redesign H.R. 5260 Reduced Costs and Continued Cures Act, issues related to international reference pricing and Part D redesign Issues related to prescription drug pricing and Part D redesign S. 2428 False Claims Amendments Act of 2021 Reimbursement for biologics/biosimilars Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Final Rule, Guidance Related to the Foreign Tax Credit and Clarification of Foreign-Derived Intangible Income Issues related to OECD negotiations on the taxation of global income H.R. 5376, Build Back Better Act S.1435 Affordable Prescriptions for Patients Act H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S 2891 Restore the America Invents Act FTC related issues, no specific bill Issues related to the Patent Act Issues related to march-in/bayh dole, WTO/TRIPS waiver, no specific bill Mergers and acquisitions, no specific bill
HCR - Health Issues MMM - Medicare/Medicaid TAX - Taxation/Internal Revenue Code CPT - Copyright/Patent/Trademark
34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
AMGEN, INC.
601 13th Street, NW, 11th Floor North, WASHINGTON, DC, 20005, US
WILLIAM O'BRIEN HELEN RHEE JESSE KERNS L NICOLE CURRIE GREGORY PORTNER VICTORIA BLATTER HOWARD MOON RUTH HOFFMAN JORDAN LYNN LAYSON WINTA MENGHIS KIMBERLY LOVE L NICOLE CURRIE HELEN RHEE JESSE KERNS VICTORIA BLATTER WILLIAM O'BRIEN HOWARD MOON RUTH HOFFMAN GREGORY PORTNER WINTA MENGHIS JORDAN LYNN LAYSON KIMBERLY LOVE L NICOLE CURRIE HELEN RHEE VICTORIA BLATTER JORDAN LYNN LAYSON HELEN RHEE L NICOLE CURRIE WILLIAM O'BRIEN VICTORIA BLATTER HOWARD MOON JESSE KERNS GREGORY PORTNER JORDAN LYNN LAYSON KIMBERLY LOVE